Laboratory of Translational Genetics, VIB Center for Cancer Biology, VIB, Leuven, Belgium.
Laboratory of Translational Genetics, Department of Human Genetics, University of Leuven (KULeuven), Leuven, Belgium.
Int J Cancer. 2020 Jun 1;146(11):3207-3218. doi: 10.1002/ijc.32797. Epub 2019 Dec 10.
Lung cancer is the number one cause of cancer-related death worldwide with cigarette smoking as its major risk factor. Although the incidence of lung cancer in never smokers is rising, this subgroup of patients is underrepresented in genomic studies of lung cancer. Here, we assembled a prospective cohort of 46 never-smoking, nonsmall cell lung cancer (NSCLC) patients and performed whole-exome and low-coverage whole-genome sequencing on tumors and matched germline DNA. We observed fewer somatic mutations, genomic breakpoints and a smaller fraction of the genome with chromosomal instability in lung tumors from never smokers compared to smokers. The lower number of mutations, enabled us to identify TSC22D1 as a potential driver gene in NSCLC. On the other hand, the frequency of mutations in actionable genes such as EGFR and ERBB2 and of amplifications in MET were higher, while the mutation rate of TP53, which is a negative prognostic factor, was lower in never smokers compared to smokers. Together, these observations suggest a more favorable prognosis for never smokers with NSCLC. Classification of somatic mutations into six-substitution type patterns or into 96-substitution type signatures revealed distinct clusters between smokers and never smokers. Particularly, we identified in never smokers signatures related to aging, homologous recombination damage and APOBEC/AID activity as the most important underlying processes of NSCLC. This further indicates that second-hand smoking is not driving NSCLC pathogenesis in never smokers.
肺癌是全球癌症相关死亡的首要原因,其主要危险因素是吸烟。尽管从不吸烟者的肺癌发病率正在上升,但这一亚组患者在肺癌的基因组研究中代表性不足。在这里,我们组建了一个由 46 名从不吸烟的非小细胞肺癌 (NSCLC) 患者组成的前瞻性队列,并对肿瘤和匹配的种系 DNA 进行了全外显子组和低覆盖率全基因组测序。我们观察到从不吸烟者的肺癌肿瘤中体细胞突变、基因组断点和染色体不稳定的基因组部分较少。较少的突变数量使我们能够确定 TSC22D1 是 NSCLC 的潜在驱动基因。另一方面,在从不吸烟者中,EGFR 和 ERBB2 等可操作基因的突变频率以及 MET 的扩增频率较高,而作为负预后因素的 TP53 突变率则低于吸烟者。总的来说,这些观察结果表明从不吸烟者的 NSCLC 预后较好。将体细胞突变分类为六种取代类型模式或九十六种取代类型特征,揭示了吸烟者和从不吸烟者之间的明显聚类。特别是,我们在从不吸烟者中发现了与衰老、同源重组损伤和 APOBEC/AID 活性相关的特征,这些是 NSCLC 的最重要潜在过程。这进一步表明,二手烟不会导致从不吸烟者的 NSCLC 发病机制。